Intestinal epithelial cells contain a high molecular weight protease subject to inhibition by anticarcinogenic protease inhibitors

Habres, Joan M.; Billings, Paul C.

doi:10.1016/0304-3835(92)90063-2

Cited by 8 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preparation of sarcoma cell protease extracts: The procedure of Habres and Billings (1992) was followed with some modifications. The tumor cells in the ascitic fluid were separated from the RBCs by Ihe procedure described above and then suspended in isotonic sucrose-lOmM Tris-HCI buffer, pH 7.0.…”

Section: Ma Terials and Methodsmentioning

confidence: 99%

Field bean protease inhibitor preparations, unlike methotrexate, can completely suppress Yoshida sarcoma tumor in rats

Banerji

Fernandes

1994

Cell Biology International

View full text Add to dashboard Cite

Protease inhibitor preparations (PIP) with antitryptic and antichymotryptic activities, isolated from field bean legume as well as doxorubicin and cyclophosphamide could effectively suppress the growth of Yoshida sarcoma ascites tumor cells transplanted in adult rats and prevent their death. As against this, methotrexate and heat-inactivated PIP were ineffective in such rats at varied doses of treatment tried. The percent survival of animals appeared to be related to the purity, treatment mode and the dose of PIP used. Zymographic analysis of the trypsin activated sarcoma cell homogenate revealed the presence of six protease bands in the molecular weight range of 51kD to 206kD. Prolonged interactions of such zymograms with protease inhibitors such as 20mM EDTA or 5mM diisopropyl flurophosphate (DIFP) or 400 micrograms/ml of PIP in reaction buffer indicated that these are not metalloproteases but serine proteases whose activities are inhibited by PIP and DIFP. Since proteases are involved in cell growth regulation and cell transformation, we hypothesize a positive relationship between the field bean protease inhibitor's blocking action on tumor cell proteases and its tumor suppressing activity.

show abstract

Section: Ma Terials and Methodsmentioning

confidence: 99%

Field bean protease inhibitor preparations, unlike methotrexate, can completely suppress Yoshida sarcoma tumor in rats

Banerji

Fernandes

1994

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…Although BBI acts to decrease cellular protease action and it is hypothesized that BBI may act directly to affect the activity of one or more proteases, specific protease targets have not been sequenced. However, a neutral serine protease has been identified as a potential substrate for BBI in mouse fibroblast cells, 112,113 and other potential protein targets have also been identified 114–116 . Yavelow et al 117 have identified two membrane bound proteases that are inhibited by BBI as well.…”

Section: Introductionmentioning

confidence: 99%

Development of the Bowman‐Birk inhibitor for oral cancer chemoprevention and analysis of neu immunohistochemical staining intensity with Bowman‐Birk inhibitor concentrate treatment

et al. 2003

View full text Add to dashboard Cite

ObjectiveslHypothesis: Cancer chemoprevention is a rapidly evolving approach to reverse or inhibit carcinogenesis, and there is active interest in development of effective chemopreventive agents against head and neck cancers. The retinoids are archetypal chemopreventive agents for oral premalignant lesions. They have significant clinical effect, but widespread use is limited by significant clinical toxicity. The Bowman-Birk Inhibitor is one of several nontoxic compounds exhibiting both potent anticarcinogenic activity and minimal toxicity. The purposes of the study were to summarize the preclinical and clinical development of Bowman-Birk Inhibitor and a Bowman-Birk Inhibitor concentrate against oral premalignant lesions and to evaluate Neu immunohistochemical staining intensity for lesions and simultaneously obtained biopsy specimens of normal-appearing mucosa from the Phase IIa Bowman-Birk Inhibitor concentrate oral leukoplakia chemoprevention trial. Study Design: Part I is a selected literature review. Part I1 is a retro- Methods: Thirty-two sets of biopsy specimens from lesions and uninvolved oral mucosa before and after treatment with Bowman-Birk Inhibitor concentrate in doses ranging from 200 to 1066 chymotrypsin inhibitory units were examined in blinded fashion for Neu immunohistochemical staining intensity using the 3B-5 monoclonal antibody. Staining intensity scores among the lesion and control biopsy specimens before and after Bowman-Birk Inhibitor concentrate treatment were analyzed and compared with previously obtained values for serum Neu, oral mucosal cell Neu, protease activity, and clinical response to treatment. Results: Mean Neu staining score was significantly higher in lesions compared with un-

show abstract

Mechanisms of Cancer Prevention: Effects of Protease Inhibitors on Proteases and Gene Expression

Kennedy

1995

Nutrients in Cancer Prevention and Treatment

View full text Add to dashboard Cite

Intestinal epithelial cells contain a high molecular weight protease subject to inhibition by anticarcinogenic protease inhibitors

Cited by 8 publications

References 27 publications

Field bean protease inhibitor preparations, unlike methotrexate, can completely suppress Yoshida sarcoma tumor in rats

Field bean protease inhibitor preparations, unlike methotrexate, can completely suppress Yoshida sarcoma tumor in rats

Development of the Bowman‐Birk inhibitor for oral cancer chemoprevention and analysis of neu immunohistochemical staining intensity with Bowman‐Birk inhibitor concentrate treatment

Mechanisms of Cancer Prevention: Effects of Protease Inhibitors on Proteases and Gene Expression

Contact Info

Product

Resources

About